share_log

Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $9

Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $9

Chardan Capital维持对Passage Bio的买入,将目标股价下调至9美元
Benzinga ·  2023/08/08 04:28

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $11 to $9.

Chardan Capital分析师Geulah Livshits维持Passage Bio(纳斯达克股票代码:PASG)的买入,并将目标股价从11美元下调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发